%0 Journal Article
%T Clinical Implications of Genomic Profile in Waldenström Macroglobulinemia.
%A Moreno DF
%A Fernández de Larrea C
%J Hematol Oncol Clin North Am
%V 37
%N 4
%D 2023 Aug 19
%M 37211494
%F 2.861
%R 10.1016/j.hoc.2023.04.002
%X With the increasing availability of sequencing techniques and new polymerase chain reaction-based methods, data regarding the genomic profile of Waldenström macroglobulinemia (WM) are being continuously analyzed and reproduced. MYD88 and CXCR4 mutations are highly prevalent in all the stages of WM, including the early IgM monoclonal gammopathy of undetermined significance or a more advanced stage, such as smoldering WM. Thus, there is a need to define genotypes before starting either standard treatment regimens or clinical trials. Here, we review the genomic profile of WM and its clinical implications while focusing on recent advances.